Journal of Alzheimer s Disease · 2023 · 10 citations · 37 references
MedicineNeurologyPharmacotherapyClinical NeuroscienceDementiaNeuroimmunologyAlzheimer DiseaseCognitive ImpairmentDementia BiomarkersDementia PharmacotherapyDementia TreatmentNeuroinflammationCognitive EffectsNeuropsychiatric EffectsNeuropsychiatric Outcome AssessmentNeuropsychiatric Symptoms Of DementiaPlacebo ComparatorsPrimary Efficacy EndpointsSecondary Efficacy EndpointsTreatment Of Cognitive Symptoms
BACKGROUND: Recent therapeutic approaches for Alzheimer's disease (AD) have had limited success. Considering the association of neuroinflammation with AD symptoms as demonstrated in multiple studies, assessment of the clinical efficacy of molecules that reduce systemic or brain inflammation is warranted. OBJECTIVE: This clinical trial assessed whether boswellic acids can improve cognitive and neuropsychiatric symptoms while reducing inflammation in AD patients. METHODS: A double-blind, placebo-controlled, study was conducted on 85 AD patients randomized to boswellic acids (K-Vie™ as the main ingredient in Memowell™) or placebo for 6 months. Clinical Dementia Rating-Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores were compared to baseline and between groups and constituted the co-primary clinical efficacy endpoints. Secondary outcomes included neuropsychiatric assessment (Neuropsychiatric Inventory-Questionnaire, NPI-Q) and assessment of AD and inflammation biomarkers. RESULTS: Patients on K-Vie™ showed a 3.1- and 1.6-unit improvement in MMSE and CDR-SOB scores, respectively, when compared to patients on placebo. NPI-Q analysis revealed significant improvement in the K-Vie™ but not in the placebo group. Only mild gastrointestinal side effects were reported in a few patients. Patients on K-Vie™ showed improvement in plasma AD biomarkers and reduction of key inflammatory cytokines including IL-6 and TNF. CONCLUSION: Our results support the positive cognitive effects of boswellic acids by reducing the systemic inflammation.
37
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
The Neuropsychiatric Inventory
Jeffrey L. Cummings, Michael S. Mega, Kevin F. Gray et al. · Neurology · 1994 · 7.6K citations
Medicine, Psychiatry, Psychology +16
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Daniel Kaufer, Jeffrey L. Cummings, Patrick Ketchel et al. · Journal of Neuropsychiatry · 2000 · 1.9K citations
Medicine, Psychiatry, Dementia +16